Walpar Nutritions Limited is an India-based company, which is engaged in manufacturing and trading of pharmaceutical, nutraceutical, herbal and ayurvedic commodities. It also manufactures various private label/third party brands for different companies across the country and overseas, as well as for their own brand sales. It is a manufacturer of various types of nutraceutical formulation, pharmaceutical ingredients, and pharmaceutical formulations. It specializes in contract manufacturing, raw materials trading, and direct selling. Its portfolio consists of tablets, capsules, powder/sachets, and oral liquids. Its products include Pcos Care Forte, Procive-F, Procive-M, Proplus, BIOMID, FERROF, FTM-plus, FTW-plus, G-Flora INOSIA-F, Joint-CR, NI-1000, Ortin-5, Ova-Wom, PCOS-CARE, Refitil-F, Refitil-M, Seagut, Spinac, TRIVITA, flaxseed- Oil, Ironica-CR, Magorich, PDF, PIYO, and Ashyuka Plus. Its subsidiaries include Walpar Wellness Private Limited and Walpar Nutri Science Private Limited.
WALPAR NUTRITIONS LIMITED Financial Highlights
- Revenue: WALPAR NUTRITIONS LIMITED reported revenue of ₹79.05 crore in FY26 vs ₹72.03 crore in FY25. It showed an increase of 9.75% on a yearly basis.
- Operating Profit: WALPAR NUTRITIONS LIMITED reported an operating profit of ₹4.10 crore in FY26 vs ₹3.88 crore in FY25. It showed an increase of 5.67% on a year-on-year basis.
- Net Profit: WALPAR NUTRITIONS LIMITED reported a net profit of ₹3.21 crore in FY26 vs ₹2.80 crore in FY25. It showed an increase of 14.64% on a yearly basis.